comparemela.com
Home
Live Updates
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis : comparemela.com
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis
/PRNewswire/ -- Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
Related Keywords
Japan
,
Canada
,
Spring House
,
British Columbia
,
Canadian
,
David Lee
,
Scandj Rheumatol
,
Prnewswire Johnson
,
Craig Stoltz
,
Exchange Commission
,
Devices Agency
,
Drug Administration
,
Johnson
,
Canadian Agency For Drugs Technologies In Health
,
European Commission
,
None Of Janssen Research Development
,
Japan Pharmaceuticals
,
National Institutes Of Health
,
Janssen Biotech Inc
,
Crohn Colitis Foundation
,
Janssen Research Development
,
Biologics License Application
,
Global Therapeutic Area Head
,
Disease Week
,
Prescribing Information
,
Medication Guidefor
,
Private Securities Litigation Reform Act
,
Janssen Research
,
Janssen Biotech
,
Annual Report
,
Note Regarding Forward Looking
,
Quarterly Reports
,
Innovative Medicine
,
Accessed February
,
Digestive Disease Week
,
Invest Dermatol
,
Canadian Agency
,
Medical Devices
,
Tremfya Report
,
Johnson Amp
,
comparemela.com © 2020. All Rights Reserved.